## Abstract We report a case involving a 26βyearβold Asian woman who developed pseudotumor cerebri (PTC) 2 years after renal transplantation. Cyclosporine A (CsA) was the only medication with a known neurotoxic side effect among her medications. CsA was discontinued and substituted with tacrolimus.
β¦ LIBER β¦
Reversible Parkinsonism after chronic cyclosporin treatment in renal transplantation
β Scribed by Helen Ling; Roongroj Bhidayasiri
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 498 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Successful Switch to Tacrolimus in a Pat
β
Sang Joon Lee; Yeon Soon Jung; Hark Rim; Bong Goo Yoo
π
Article
π
2009
π
Wiley (John Wiley & Sons)
π
English
β 122 KB
π 1 views
Treatment of lymphocele in renal transpl
β
L. Sibert; G. Descargues; M. Scotte
π
Article
π
1995
π
John Wiley and Sons
π
English
β 132 KB
π 1 views
Treatment of lymphocele in renal transpl
β
Dr M. Schilling; D. Abendroth; R. Kunz
π
Article
π
1995
π
John Wiley and Sons
π
English
β 318 KB
π 1 views
Successful allogeneic bone marrow transp
β
Dr. J. P. Vernant; M. Rodet; H. Rochant; F. Feuilhade; A. Thuran; P. Bierling; M
π
Article
π
1981
π
John Wiley and Sons
π
English
β 193 KB
π 2 views
Entecavir treatment for chronic hepatiti
β
Ezequiel Ridruejo; RaΓΊl Adrover; Cristina Alonso; Oscar G. MandΓ³; Marcelo O. Sil
π
Article
π
2010
π
Wiley (John Wiley & Sons)
π
English
β 73 KB
Mycophenolate mofetil in combination wit
β
Georges-Philippe Pageaux; Lionel Rostaing; Yvon Calmus; Christophe Duvoux; Clair
π
Article
π
2006
π
John Wiley and Sons
π
English
β 92 KB
π 1 views
The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk. In this prospective, multicenter, randomized study, chronic CNI-related renal dysfunction was